

NCI Director's Report


Norman E. Sharpless, M.D.

*2nd Virtual Joint Meeting of NCI Board of Scientific
Advisors & National Cancer Advisory Board*

June 15, 2020

@NCIDirector
@TheNCI

Appropriations Outlook



FY 2021

NCI Response to COVID-19

- Flexibilities and opportunities for grantees, especially trainees
- Guidance for cancer clinical trials
- SARS-CoV-2 serology research
- NCI COVID-19 in Cancer Patients Study (NCCAPS)
- Genomic studies of COVID-19 outcomes
- Clinical trials of immunomodulatory agents

[*https://www.cancer.gov/coronavirus-researchers*](https://www.cancer.gov/coronavirus-researchers)

COVID-19 Serology Research

Serological Sciences Network for COVID-19 (SeroNet)

RFA-CA-20-038

SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional)

RFA-CA-20-039

Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)



Coronavirus (COVID-19) Update: Serological Test Validation and Education Efforts
Insight into FDA's Revised Policy on Antibody Tests: Prioritizing Access and Accuracy



134 STAT. 620 PUBLIC LAW 116-139—APR. 24, 2020

Public Law 116-139
116th Congress

An Act

Apr. 24, 2020 [H.R. 266] Making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2019, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.
This Act may be cited as the “Paycheck Protection Program and Health Care Enhancement Act”.

SEC. 2. TABLE OF CONTENTS.
The table of contents for this Act is as follows:

Sec. 1. Short title.
Sec. 2. Table of contents.
Sec. 3. References.

Paycheck Protection Program and Health Care Enhancement Act.
15 USC 9001 note.

Cancer & COVID-19 Natural History

NIH NATIONAL CANCER INSTITUTE

Home > News & Events > Cancer Currents Blog

How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find Out

Subscribe

May 21, 2020, by James H. Doroshow, M.D.

With the sudden explosion of the COVID-19 pandemic, we are all living with a great deal of fear, uncertainty, and anxiety. As an oncologist and cancer researcher, I know that those feelings are heightened for many people with cancer.



People with cancer are already facing the shock of a cancer diagnosis, the tribulations that accompany treatment, or the stress of survivorship. On top of that, we're learning that people with cancer may be at higher risk of severe illness from COVID-19 because their cancer, or its treatment, has left them more vulnerable to complications.


NCI has launched a study called NCCAPS that will help scientists answer questions about COVID-19's impact on cancer patients and cancer's impact on the course of COVID-19.
Credit: iStock

NCI COVID-19 in Cancer Patients Study (NCCAPS)

- **448 trial sites** activated as of June 12
- Aim to enroll 2,000 patients
- *NCT04387656*


Impacts of the COVID-19 pandemic on long-term trends in cancer statistics

Delayed Diagnosis	<ul style="list-style-type: none"> • Reduced screening • Reduced follow-up on suspicious findings from screening • Reduced visits to address symptoms 	Treatment Delay Increased Mortality
Deferred Care	<ul style="list-style-type: none"> • Postponed surgery • Postponed radiation • Postponed chemotherapy 	Treatment Delay Increased Mortality
Reduced / Non-Standard care	<ul style="list-style-type: none"> • Less intense chemotherapy • Neo-adjuvant chemo instead of immediate surgery 	Reduced Response Increased Mortality



Modeling Potential Effects of the Pandemic on Cancer Mortality

Percent Excess Breast and Colorectal Cancer Deaths Per Year
Compared to a Scenario without Delayed Screening and Diagnosis



Liver Cancer Screening



NCI Press Release

NIH scientists develop blood test to help improve liver cancer screening



Posted: June 11, 2020

Contact:
NCI Press Office
240-760-6600

NCI CCR LIVER CANCER PROGRAM

A multidisciplinary network of researchers and clinicians dedicated to improving early detection, diagnosis and treatment of liver cancer.

Cell

CellPress

Article


A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma

Jinping Liu,^{1,10} Wei Tang,^{2,10} Anuradha Budhu,^{1,3} Marshonna Forgues,¹ Maria O. Hernandez,¹ Julián Candia,¹ Yujin Kim,¹ Elise D. Bowman,¹ Stefan Ambs,² Yongmei Zhao,⁴ Bao Tran,⁴ Xiaolin Wu,⁴ Christopher Koh,⁵ Pallavi Surana,⁵ T. Jake Liang,⁵ Maria Guarnera,⁶ Dean Mann,⁶ Manoj Rajaure,⁷ Tim F. Greten,^{8,3} Zhanwei Wang,⁹ Herbert Yu,⁹ and Xin Wei Wang^{1,3,11,*}

Pancreatic Cancer & New Onset Diabetes

About **1 in 100** people with **new onset diabetes** are diagnosed with pancreatic cancer **within 3 years** of their diabetes diagnosis

1 in 4 people diagnosed with pancreatic cancer were first diagnosed with diabetes.



New Onset Diabetes Study

With the National Institute of Diabetes and Digestive and Kidney Diseases

Cohort study recruiting 10,000 people aged 50-85 with newly diagnosed diabetes (439 enrolled to date)

Enrolling at 12 sites in 9 states
Partnering with Pancreatic Cancer Action Network

Leadership Updates



Emily S. Tonorezos, MD, MPH
Director
Office of Cancer Survivorship



Philip E. Castle, Ph.D.
Director
Division of Cancer Prevention

NCI Bottom Line: A Blog About Grants & More



*NCI Presents 13 Research
Concepts to Board
of Scientific Advisors*
Dr. Paulette Gray



*Cancer Research in
the Era of COVID-19*
Dr. Dinah Singer



*Cancer Research Training
in the Era
of COVID-19*
Dr. Oliver Bogler

Thank you!